Adipo Therapeutics is focused on addressing the obesity epidemic by leveraging the unique properties of brown fat to enhance energy expenditure. Their innovative approach involves converting white adipose tissue, which primarily stores energy, into metabolically active brown adipose tissue that burns energy. This transformation is facilitated through the use of Notch-inhibiting nanoparticles, which are designed to be injected directly into adipose tissue. This localized delivery method allows for sustained intracellular release of the Notch inhibitor, promoting mitochondrial biogenesis and the browning of white fat without necessitating changes in caloric intake. Preclinical studies have shown promising results, indicating that this method can lead to weight loss and improved metabolic health, including better blood glucose and lipid control.

The lead product of Adipo Therapeutics, ADPO-002NP, utilizes biodegradable poly(lactide-co-glycolide) (PLGA) nanoparticles to achieve its therapeutic effects. This technology not only minimizes systemic toxicity and side effects due to its localized action but also offers a self-administered weekly injection option for patients. The mechanism of action involves the inhibition of the Notch signaling pathway, which plays a crucial role in regulating metabolism and promoting the conversion of white fat to brown fat. By enhancing energy expenditure and improving insulin sensitivity, Adipo Therapeutics aims to provide a novel treatment option for obesity and related metabolic disorders, potentially transforming the landscape of obesity management.

United States

Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes.

Adipo Therapeutics

Company Details